Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 3/20 | 0.41 |
| ▸ | CTSB | P07858 | 2/20 | 0.39 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.39 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4383909 | 0.94 | GAA (0.57) | GAATDP1ALDH1A1KMT2AMEN1 | |
| SCHEMBL4378457 | 0.86 | GAA (0.49) | GAATDP1ALDH1A1KMT2AMEN1 | |
| SCHEMBL15910820 | 0.82 | TDP1 (0.47) | GAATDP1ALDH1A1KMT2AMEN1 | |
| SCHEMBL4378946 | 0.80 | GAA (0.51) | GAA | |
| SCHEMBL4383955 | 0.80 | GAA (0.46) | GAAALDH1A1 | |
| SCHEMBL19586788 | 0.79 | CRBN (0.55) | GAATDP1ALDH1A1 | |
| SCHEMBL30600396 | 0.79 | CRBN (0.55) | GAATDP1ALDH1A1 | |
| SCHEMBL7472269 | 0.75 | GAA (0.67) | GAATDP1ALDH1A1KMT2AMEN1 | |
| SCHEMBL1896757 | 0.75 | DHODH (0.38) | CYP3A4 | |
| SCHEMBL3752114 | 0.75 | GAA (1.00) | GAATDP1ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937643-B1 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | SECOND GENOME INC (US) | 2016-07-13 | — | — | EP | disclosed |
| EP-1937643-B1 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | SECOND GENOME INC (US) | 2016-07-13 | — | — | EP | disclosed |
| US-8779144-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | EVOTEC (US) INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8779144-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | EVOTEC (US) INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8779144-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | EVOTEC (US) INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20110118287-A1 | Bicycloheteroaryl Compounds As P2X7 Modulators and Uses Thereof | RENOVIS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110118287-A1 | Bicycloheteroaryl Compounds As P2X7 Modulators and Uses Thereof | RENOVIS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110118287-A1 | Bicycloheteroaryl Compounds As P2X7 Modulators and Uses Thereof | RENOVIS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20090298825-A1 | Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | RENOVIS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-20090298825-A1 | Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | RENOVIS, INC. | 2009-12-03 | — | — | US | disclosed |
| EP-1937643-A2 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | Renovis, Inc. (US) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007109160-A9 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS INC (US) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007109160-A9 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS INC (US) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007109160-A2 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007109154-A2 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007109160-A2 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298825-A1 | Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX1 | GAA 4090/4885TDP1 2273/4885ALDH1A1 3109/4885 |
| US-20110118287-A1 | Bicycloheteroaryl Compounds As P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX1 | GAA 4075/4885TDP1 2212/4885ALDH1A1 3160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.